Literature DB >> 12125921

Clinical utility of telangiectasia of hands in scleroderma and other rheumatic disorders.

Peter J Robert-Thomson1, Tiffany L Mould, Jennifer G Walker, Malcolm D Smith, Michael J Ahern.   

Abstract

Telangiectasia of the hands were observed in 76% of patients with scleroderma (n = 53) as compared with 12% of patients with other rheumatic disorders (n = 100) and in 13% of healthy subjects (n = 30). In scleroderma, telangiectasia of the hands were commonly multiple (mean number +/- SD = 22.9+/-30.1) with 7.3% being >1 mm in size. They were found in greater numbers in those patients with the limited subtype. The distribution of telangiectasia was observed on all but 4 of 158 sectors of the hand with significant higher numbers on the ventral surface of the digits. Significant associations of telangiectasia of the hands were also observed with numbers of telangiectasia on face and lips (p = 0.001), disease duration (p = 0.002), surface area of digital calcinosis (p = 0.03) and with the presence of the centromere antibody (p = 0.005). Possible associations were observed with prior gastrointestinal bleeds (particularly with telangiectasia >1 mm) and with isolated pulmonary hypertension. No significant correlation was found between number of telangiectasia and with nailfold capillary size or density. In conclusion, multiple telangiectasia of the hands were most commonly observed in patients with the centromere positive, limited subtype of scleroderma of long duration. Their pathogenesis is unknown.

Entities:  

Mesh:

Year:  2002        PMID: 12125921

Source DB:  PubMed          Journal:  Asian Pac J Allergy Immunol        ISSN: 0125-877X            Impact factor:   2.310


  4 in total

1.  Whole-Body Distribution and Clinical Association of Telangiectases in Systemic Sclerosis.

Authors:  Mathieu Jouvray; David Launay; Sylvain Dubucquoi; Vincent Sobanski; Céline Podevin; Marc Lambert; Sandrine Morell-Dubois; Hélène Maillard; Pierre-Yves Hatron; Eric Hachulla; Jonathan Giovannelli
Journal:  JAMA Dermatol       Date:  2018-07-01       Impact factor: 10.282

Review 2.  Patient-reported outcome instruments in clinical trials of systemic sclerosis.

Authors:  John D Pauling; Joana Caetano; Corrado Campochiaro; Giacomo De Luca; Ana Maria Gheorghiu; Maria Grazia Lazzaroni; Dinesh Khanna
Journal:  J Scleroderma Relat Disord       Date:  2019-11-25

3.  Telangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertension.

Authors:  Ami A Shah; Fredrick M Wigley; Laura K Hummers
Journal:  J Rheumatol       Date:  2009-12-01       Impact factor: 4.666

4.  Diagnostic value of chest spiral CT scan and Doppler echocardiography compared to right heart catheterization to predict pulmonary arterial hypertension in patients with scleroderma.

Authors:  Siavash Kooranifar; Roozbeh Naghshin; Seyed Hashem Sezavar; Shokoufeh Hajsadeghi; Seyed Mehdi Talebzadeh
Journal:  Acta Biomed       Date:  2021-01-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.